Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXG102-031 in wAMD
NCT06183814Phase 2Recruiting
- Sponsor
- Hangzhou Jiayin Biotech
- Start
- Oct 2023
- Primary completion
- Dec 2025
- Modality
- Gene Editing, Gene Silencing, AAV Vectors
- Countries
- 1
01
Overview
A Phase 2 trial of EXG102 in neovascular age-related macular degeneration (NVAMD), sponsored by Hangzhou Jiayin Biotech. Started Oct 2023; status: recruiting.
02
Drugs
EXG102
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT06183814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06183814.